Benchling is a cloud platform built for biotech R&D - a single, biology-first system of record where scientists design experiments, track samples, manage molecular data, and collaborate. Founded in 2012 out of MIT, it has grown into the operating system for modern life science, used by hundreds of thousands of scientists at companies ranging from startups to the largest biopharma firms, and is now embedding AI agents and predictive models directly into the lab workflow.
Neiman Mathew is a Partner at Greylock, one of Silicon Valley's most storied venture capital firms, where he focuses on early-stage founders building the next generation AI stack. He skipped college to pursue technology, spending years at Hex Labs applying AI to materials discovery and at Schmidt Futures funding ambitious AI-for-science research before joining Amplify Partners and then Greylock. Known for engaging founders before they even have a business idea, Mathew brings a rare combination of deep scientific intuition and investor pattern-recognition to the earliest and most uncertain bets in AI.